The recently launched research project Relent aims at developing new, individualized therapies for autoimmune diseases like rheumatism and multiple sclerosis. The project will be carried out by a multidisciplinary consortium of nine scientific partners and four SME’s from Europe, the US and Australia. Among the partners is KTH Royal Institute of Technology/SciLifeLab where the research will be led by Peter Nilsson at SciLifeLab:s national unit Protein and Peptide Arrays.
“We will have the opportunity to use our expertise and technology for protein analysis and large scale investigations of autoimmune diseases in a very interesting medical context.” Said Peter Nilsson. “The constellation with a number of clinical research groups and pharma companies, with access to large and well defined panels of blood samples, together with vast knowledge about autoimmunity, is of course very interesting for us.”
Relent is funded with six million Euros for four years by the European Commission within Horizon 2020.